• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ticagrelor and aspirin vs. aspirin alone for ischemic stroke or TIA

byConstance Wu
August 10, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Ticagrelor and aspirin taken after a mild-to-moderate acute non-cardioembolic stroke or high-risk transient ischemic attack led to a lower rate of subsequent stroke within 30 days.

2. The incidence of overall disability at 30 days did not differ between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Following an acute ischemic stroke or transient ischemic attack (TIA), the risk of a subsequent ischemic stroke is estimated to be 5-10% within the first few months. A number of trials have sought to examine the role of antiplatelet agents to mitigate such a risk. Ticagrelor is a P2Y-12 inhibitor increasingly employed as part of dual antiplatelet therapy (DAPT) following myocardial infarction and coronary reperfusion. Evidence from prior subgroup analyses has suggested its potential benefit when used in combination with aspirin after an ischemic stroke. This multi-center, placebo-controlled, randomized controlled trial found use of aspirin and ticagrelor following a mild-moderate acute non-cardioembolic stroke or TIA to reduce the composite risk of stroke or death within thirty days when compared with use of aspirin alone. Such a finding provides further evidence in support of a short-term role of DAPT therapy following acute stroke, demonstrating a magnitude of benefit similarly exhibited in previous studies examining DAPT therapy within this setting. However, caution must be exercised in interpreting the study’s principal finding. The report of a reduced rate of stroke or death, while both included in the pre-defined primary outcome, fails to qualify the nearly equivalent all-cause mortality rate observed at thirty days in both groups. Differences in the presented primary outcome are explained largely by the reduced rate of ischemic stroke at 30 days. It should be noted there was no incident reduction in disability at 30 days between groups and a higher rate of severe bleeding – including rates of intracranial hemorrhage or fatal bleeding – was observed in those taking both aspirin and ticagrelor. The study may benefit from further characterization of functional outcomes to better delineate the risk, benefit profile.

Click here to read the study, published today in NEJM

Relevant Reading: Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack: An Overview of Major Trials and Meta-Analysis

In-Depth [randomized controlled trial]: A total of 11,016 patients were enrolled and underwent randomization across 414 sites in twenty-eight countries from January 2018 until October 2019. Patients were eligible if they were found to have a mild-to-moderate acute noncardioembolic ischemic stroke or a high-risk TIA and were not planned for an endovascular intervention, including thrombectomy or thrombolysis. Randomization occurred within twenty-four hours of symptom onset or last known normal. Subjects were loaded and maintained on either aspirin and ticagrelor or aspirin and placebo for at least thirty days, after which antiplatelet therapy was left to the discretion of study site investigators. Follow-up data was collected at approximately five, thirty, and sixty days following randomization.  The primary-outcome event rate, defined as a composite risk of stroke or death within 30 days of follow-up, was lower in those taking aspirin and ticagrelor (5.5%) when compared to those taking aspirin alone (6.6%), (HR 0.83, 95% CI 0.71-0.96). The rate of ischemic stroke was lower in those taking aspirin and ticagrelor group (5.0% vs 6.3%, HR 0.79, 95% CI 0.68-0.93). No significant difference was seen in the rate of death (HR 1.33, 95% CI 0.81-2.19) or overall disability at 30 days (OR 0.98, 95% CI 0.89-1.07). A higher rate of severe bleeding was seen in 0.5% of those in the ticagrelor group, compared to 0.1% in those taking placebo (HR 3.99, 95% CI 1.74-9.14). Permanent discontinuation due to bleeding or dyspnea occurred in 3.8% of those in the aspirin and ticagrelor group, compared to 0.8% in those taking aspirin alone.

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

mRNA-1273 SARS-CoV-2 vaccine likely effective in nonhuman primates

Next Post

Ofatumumab may reduce annual relapse rates compared to teriflunomide in multiple sclerosis

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series
Pediatrics

Homicide deaths are on the rise for children living in the United States

January 30, 2023
Next Post
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)

Ofatumumab may reduce annual relapse rates compared to teriflunomide in multiple sclerosis

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

2 Minute Medicine Rewind August 10, 2020

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Usage of first-line antidepressant medications in early pregnancy associated with selected birth defects

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options